Lilly says retatrutide beat top-dose Ozempic in a phase 3 type 2 diabetes trial
Over 80 weeks, people on the 12mg dose lost 47.4 lbs on average versus 20.9 lbs on Ozempic 2mg, Lilly says. It plans to file with the FDA in early 2027.
Recap by typeshit. Full story at ABC13 Houston.